Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OptimUM-11 adjuvant darovasertib + crizotinib versus observation in high-risk primary uveal melanoma
MOH_2026-09-14_017033Phase 3Not yet recruiting
- Sponsor
- IDEAYA Biosciences
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in intraocular melanoma comparing Darovasertib + crizotinib with Observation (2 arms). Primary endpoint: Recurrence-free survival. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
darovasertibcrizotinib
03
Conditions
intraocular melanoma
Beyond the preview
Go deeper on MOH_2026-09-14_017033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-09-14_017033.